NCT01443273|Unknown
Loading search results
Sponsor study identifier
observational
50
1 country
1
Study Start
October 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
There are several factor that can be related to Neonatal Thrombotic events. Among them hypercoagulability can be the cause of those events. Factor V Leiden (FVL) and Prothrombin mutation are the most common causes of hereditary thrombophilia. The incidence of in the arab population is known to be higher than the incidence in another western populations. The purpose of this study is to review retrospectively the thrombophilic risk factors that were found in a cohort of premature babies and term newborns treated and investigated at the Neonatal Intensive Care Unit and at the Pediatric Hematology Unit.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 27, 2011
Actual (reported)September 29, 2011
Actual (reported)October 2011
Date type not reportedThis date has not been verified as actual or estimated.
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The frequency of thrombophilic risk factors in preterms and infants
Recruitment of all premature and term infants born at Emek Medical Center and suffer from thrombotic events.
One year
All infants (premature and term) diagnosed at the Neonatal Intensive Care Unit with thrombotic events
No interventions will be done related to the study besides summary of the Medical Files.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
All newborns (Term and Premature) diagnosed with Neonatal Thrombotic events between year 1990 to 2010.
Contact the study team to confirm eligibility.
Pediatric Hematology Unit - HaEmek Medical Center
Afula, 18101, Israel
Carina Levin, MD
Pediatric Hematology Unit - Ha'Emek Medical Center
First Submitted
September 27, 2011
First Posted
September 29, 2011
Study Start
October 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 31, 2020
Vitamin K2 Intervention in Patients With Vitamin K Antagonists
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
November 1, 2019
Record last verified: 2019-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: